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Abstract: Interleukin (IL)-8 (CXCL8), a chemokine involved in neutrophil recruitment, has been
implicated in ductular reaction and liver fibrogenesis. We studied liver and serum IL-8 expression
in a large biliary atresia (BA) cohort and explored its prognostic and pathophysiological potential.
IL-8 expression was assessed in liver utilizing quantitative polymerase chain reaction (qPCR), immunohistochemistry and in situ hybridization and in serum using an enzyme-linked immunosorbent
assay, among 115 BA patients, 10 disease controls and 68 normal controls. Results were correlated to
portoenterostomy (PE) outcomes, biochemical and histological liver injury, transcriptional markers
of fibrosis and cholangiocytes, and expression of other related cytokines. IL-8 was markedly overexpressed in liver and serum of BA patients at PE (n = 88) and in serum samples obtained during
postoperative follow-up (n = 40). IL-8 expression in the liver was predominantly in cholangiocytes
within areas of ductular reaction. Liver IL-8 mRNA expression correlated positively with its serum
concentration, bile ductular proliferation, Metavir fibrosis stage, and transcriptional markers of
activated myofibroblasts (ACTA2) and cholangiocytes (KRT19). Taken together, IL-8 may mediate
liver injury in BA by promoting ductular reaction and associated liver fibrogenesis. Prognostic value
of serum IL-8 to predict native liver survival was limited and confined to the postoperative period
after PE.
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Biliary atresia (BA), presenting in the neonatal period, is characterized by fibroinflammatory obliteration of the extra- and intrahepatic bile ducts. Although its exact
etiology remains elusive, previous studies have at times suggested a developmental, dysfunctional immune response or environmental toxin hypotheses either individually or
in some combination [1,2]. Untreated, the resulting bile duct disruption and cholestasis
rapidly progresses to fatal biliary cirrhosis and end-stage liver disease within 2 years from
birth [2,3]. The current management of BA involves an early attempt at restoration of
bile flow with excision of the obliterated extrahepatic bile ducts and biliary reconstruction
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using a Roux jejunal loop (portoenterostomy (PE)) [2]. Consequent normalization of serum
bilirubin levels is then regarded as a successful outcome. Although PE is successful in over
half of the patients, progressive fibrosis continues in their native livers necessitating liver
transplantation (LT) in the majority of patients before the age of 20 years [3]. Consequently,
BA is the leading cause of LT in children [4].
The highly variable surgical prognosis of BA necessitates intensive postoperative
monitoring [5]. Reliable tools for prediction of the outcome of PE and progression of liver
injury are limited [5,6], but urgently needed for individualized patient follow-up, family
counselling and early prediction of the need for LT as well as interventional studies [7]. A
chemokine, interleukin (IL)-8 or CXCL8, mediates innate immune activation and regulates
neutrophil recruitment and degranulation [8]. Increased IL-8 expression has been linked
with reactive cholangiocytes in ductular reaction (DR) and progression of liver fibrosis in
other chronic liver diseases in accordance with the ability of IL-8 to induce alpha-smooth
muscle actin (α-SMA), a marker of myofibroblast activation [9,10]. Numerous studies have
shown that IL-8 expression is increased in patients with BA and experimental data suggest
that IL-8 might contribute to disease progression [8,11–13]. However, a recent study has
reported that tissue and serum levels of IL-8 of BA patients at the time of PE were not
related to the outcome [14]. Thus the pathophysiological significance and the role of IL-8
as a biomarker for liver injury and thereby its predictive ability for PE outcomes has not
been yet fully established [3].
The aim of this study was to explore the prognostic and pathophysiological potential
of IL-8 in BA by assessing its serum and liver expression in a controlled manner. We
hypothesized that by correlating with liver fibrogenesis, IL-8 expression could serve as a
valuable prognostic biomarker for the success of PE and native liver survival thereafter.
To this end, we assessed liver expression and serum levels of IL-8 and other connected
cytokines including IL-18, IL-33, tumor necrosis factor-alpha (TNFα) and interferon gamma
(IFN-γ) at PE. We extend previous knowledge by addressing IL-8 expression also during
postoperative follow-up and by relating IL-8 in a large patient cohort to histological liver
fibrosis, bile ductular proliferation and transcriptional markers indicative of active liver
fibrogenesis and cholangiocytes as well as surgical outcomes.
2. Materials and Methods
2.1. Patients and Controls
This was a retrospective observational study. We included all BA patients with stored
serum or liver samples, who had undergone PE at King’s College Hospital, London,
UK, during 2005–2013 or the Children’s Hospital, University of Helsinki, Finland during
2012–2018. Of the 115 included patients representing 33% and 90% of all patients operated
on in London and Helsinki during the same eras, 75 had available samples obtained at
PE, 27 during post-PE follow-up and 13 at both time points (Table 1). Follow-up samples
were collected from stable patients in Helsinki during 2012–2018, where serum samples
were obtained at least yearly and liver biopsies at 1 year post-PE and once in 5 years
thereafter as a part of routine clinical follow-up [15]. Wedge liver biopsies were taken at
PE, and ultrasound guided core needle biopsies under general anesthesia for endoscopic
variceal surveillance as described previously [15]. Liver biopsy is not part of the clinical
management of patients post-operatively at King’s College Hospital. All PE surgeries were
open and postoperative steroids, ursodeoxycholic acid and antibiotics were routinely used
in both centers [15]. The diagnosis of BA was confirmed by histopathological assessment
of bile duct remnants in both centers.
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Table 1. Baseline patient characteristics and included study samples for all patients (n = 115), this included patients with
samples only at portoenterostomy (PE) (n = 75) and patients with samples only at follow-up (n = 27) as well as 13 patients
with samples both at PE and follow-up. Data are median (interquartile range) or frequencies (%).
All Patients
(n = 115)

Patients at PE
(n = 88)

Patients at Follow Up
(n = 40)

Age at PE, days

56 (41–76)

55 (41–75)

56 (35–76)

Follow up after PE, years

3.6 (1.1–9.7)

2.1 (0.7–6.6)

9 (3.6–11.7)

Type of BA, n (%)
1 or 2
3

5 (4%)
110 (96%)

1 (1%)
87 (99%)

5 (13%)
35 (87%)

Splenic malformation, n (%)

17 (15%)

11 (13%)

8 (20%)

Cystic disease, n (%)

15 (13%)

12 (14%)

5 (13%)

Clearance of Jaundice, n (%)

74 (64%)

47 (53%)

38 (95%)

Liver transplantation, n (%)

56 (49%)

49 (56%)

10 (25%)

Age at liver transplantation, year

1.5 (0.8–3.0)

1.2 (0.7–2.3)

6.9 (2.5–9.4)

Died without transplantation, n

3

3

0

Bilirubin total, µmol/L

132 (18–167)

145 (124–177)

10 (5–17)

GGT (U/L)

329 (107–673)

572 (235–873)

62 (25–162)

AST (U/L)

165 (94–232)

196 (143–260)

74 (52–122)

ALT (U/L)

84 (44–123)

112 (64–163)

48 (24–98)

APRi

0.84 (0.49–1.43)

0.83 (0.5–1.23)

1.2 (0.48–1.92)

Number of patients with Serum IL-8 samples

n = 109

n = 77

n = 40

Number of Serum IL-8 samples/patient

1

1

3 (2–4)

Number of patients with liver biopsies

n = 82

n = 66

n = 22

Number of liver biopsies/patient

1

1

2 (1–2)

Liver biochemistry

Included serum and liver samples

BA: biliary atresia; PE: portoenterostomy; GGT: gamma-glutamyl transferase; AST: aspartate transaminase; ALT: alanine aminotransferase;
APRi: AST-to-platelet ratio index; IL-8: Interleukin-8.

Serum samples from 68 generally healthy pediatric day surgery patients and 10 pediatric donor liver biopsies were used as normal controls, and 10 liver biopsies from children
with other cholestatic disorders as disease controls. Clinical details of disease controls are
displayed in Supplementary Table S1.
2.2. Liver Biochemistry and Histology
Serum levels of bilirubin, alanine aminotransferase (ALT), aspartate transaminase
(AST), AST-to-platelet ratio index (APRi) and gamma-glutamyl transferase (GGT) were
measured by the local hospital laboratories. Liver biopsies were graded for fibrosis using
the Metavir staging and scored for cholangiocyte marker cytokeratin (CK)-7 positive bile
ductular proliferation (0–2) and portal inflammatory cell infiltration (0–3) by an experienced
pediatric liver pathologist blinded to the clinical data as described previously [15,16].
2.3. Serum Cytokine Levels
Serum concentrations of IL-8, IL-18 and TNF-α were determined using commercially available Q-Plex multiplex ELISA (enzyme-linked immune sorbent assay) array kits
(Quansys Bioscience, Logan, UT, USA) following the manufacturer’s instructions.
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2.4. Liver mRNA Expression
RNA from liver biopsies was extracted using the RNeasy Mini Kit (QIAGEN, Frederick,
MD, USA). RNA concentration was assessed spectrophotometrically. mRNA expression
of IL-8, IL-18, IL-33, TNF-α, IFNG, COL1A2, ACTA2, KRT7 and KRT19 were analyzed
in triplicate by quantitative real-time polymerase chain reaction (qPCR) using Custom
RT Profiler PCR Array (CAPH12366A) (QIAGEN SABiosciences, Frederick, MD, USA)
on BIO-RAD CFX384 Real-Time System (Bio-Rad, Hercules, CA, USA) according to the
manufacturer’s instructions. ACTA2 (marker of myofibroblast activation) and COL1A2
(marker of collagen production) were studied as surrogates for active liver fibrogenesis,
and KRT7 and KRT19 as cholangiocyte markers, while HPRT1, GAPDH, ACTB and B2M
were used as housekeeping genes. Quantification of target gene mRNA expression was
performed using the ∆∆Ct method and expressed after normalization to housekeeping
genes and relative to normal control subjects.
2.5. Immunohistochemistry
Formalin fixed, paraffin embedded (FFPE) sections were deparaffinized, hydrated,
and treated with target retrieval solution pH 9 (Dako - Agilent Technologies, Glostrup,
Denmark). Commercially available antibody for IL-8 (rabbit polyclonal, AHC0881, ThermoFisher Scientific, Waltham, MA, USA) was used at a dilution of 1:3000 along with
the Novolink TM polymer detection system (Leica biosystems Newcastle Ltd, Newcastle Upon Tyne, UK). Primary antibody was incubated overnight at 40 ◦ C. Images were
generated using 3DHISTECH Panoramic 250 FLASH II digital slide scanner at Genome
biology unit supported by HiLIFE and the Faculty of Medicine, University of Helsinki, and
Biocenter Finland.
2.6. RNA In Situ Hybridization
RNA in situ hybridization was performed on fresh 4.5 µm FFPE tissue sections using
RNAscope Multiplex Fluorescent Reagent Kit Version 2 (#323100, Advanced Cell Diagnostics, Newark, CA, USA) for target detection according to the manual. Tissue sections were
baked for 1 h at 60 ◦ C, then deparaffinized and treated with hydrogen peroxide for 10 min
at room temperature (RT). Target retrieval was performed for 15 min at 98 ◦ C, followed by
protease plus treatment for 15 min at 40 ◦ C. All probes (Hs-ONECUT1 (HNF6) #490081, HsIL-8 #310381, 3-Plex negative control probe dapB #320871 and 3-plex positive control probe,
POLR2A, PPIB, UBC #320861, Advanced Cell Diagnostics, Newark, CA, USA) were hybridized for 2 h at 40 ◦ C followed by signal amplification and developing of HRP channels
undertaken according to the manual. TSA Plus fluorophores fluorescein (1:1000 dilution),
Cyanine 3 (1:1500 dilution) and Cyanine 5 (1:3000 dilution) (NEL744001KT, PerkinElmer,
Waltham, MA, USA) were used for signal detection. The sections were counterstained with
DAPI (4’, 6-diamidino-2-phenylindole) and mounted with ProLong Gold Antifade Mountant (P36930, Invitrogen ThermoFisher Scientific, Waltham, MA, USA). Tissue sections were
scanned using 3DHISTECH Panoramic 250 FLASH II digital slide scanner at Genome Biology Unit (Research Programs Unit, Faculty of Medicine, University of Helsinki, Biocenter,
Finland) using 1 × 20 magnification with extended focus and 7 focus levels.
2.7. Statistical Methods
Unless otherwise stated, continuous variables were expressed as medians with interquartile ranges and compared using the Mann–Whitney U test. Multiple group comparisons were undertaken using the Kruskal–Wallis test. Correlations were tested with
Spearman’s rank correlation between different variables analyzed from the same liver
biopsy or from simultaneously obtained liver and serum samples. To address effects of
different expression levels on native liver survival, Kaplan–Meier analysis with log-rank
test was used to predict native liver survival between tertiles for serum IL-8 concentration
and relative liver mRNA expression. p < 0.05 was considered as statistically significant and
all analyses were done on RStudio version 1.2.5033 (RStudio, Boston, MA, USA). Numbers
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committee (protocol
number
345/03/1372008)
andthethe
institutional
board on 21
dures followed
were
in accordance with
ethical
standards review
of the responsibility
commitJuly 2017 (§68tee
HUS/149/2017)
and
also
by
the
National
Research
Ethics
Committee
the
on human experimentation (institutional/national) and with the Helsinkiof
Declaration
of 1975,
revised in 2008.
study was
approved
by of
thesamples
hospital in
ethical
committee
UK (12/WA/0282
andas18/SC/0058).
An The
informed
consent
for use
research
number 345/03/1372008) and the institutional review board on 21 July 2017
was obtained (protocol
from all patients.
3. Results

(§68 HUS/149/2017) and also by the National Research Ethics Committee of the UK
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obtained from all patients.

3.1. Patient Characteristics

3. Results
Patient characteristics
are listed in Table 1. The median patient age at the time of
Characteristics
surgery was 3.1.
56 Patient
days (41–76),
and 96% of the children presented with type 3 BA.
Patient
characteristics
listed in Table
1. serum
The median
patient
ageμmol/L),
at the time of
Following PE, 74 (64%) of the patientsare
normalized
their
bilirubin
(<20
surgery
was
56
days
(41–76),
and
96%
of
the
children
presented
with
type
3
BA.
Following
and 56 (49%) underwent LT at median age of 1.5 years (interquartile range (IQR) 0.8–3.0).
PE, 74 (64%) of the patients normalized their serum bilirubin (<20 µmol/L), and 56 (49%)
Native liver survival was 77% (95% confidence interval (CI) 70–85), 69% (95% CI 61–78)
underwent LT at median age of 1.5 years (interquartile range (IQR) 0.8–3.0). Native liver
and 56% (95%survival
CI 47–66)
at 1, 2 and 5 years respectively.
was 77% (95% confidence interval (CI) 70–85), 69% (95% CI 61–78) and 56% (95%
CI 47–66) at 1, 2 and 5 years respectively.

3.2. Liver Expression and Serum Levels of Interleukin-8 (IL-8) Were Increased and Intercorrelated
Liver Expression
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mRNA
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PE (nWere
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Liver
IL-8
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when
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1a).
to
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(by
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and
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(by
9-fold)
control
groups
(p
<
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(Figure
Similar to the upregulated liver expression, we found a significant, over 15-fold increase (p 1a).
Similar to the upregulated liver expression, we found a significant, over 15-fold increase
< 0.001) in IL-8 serum levels at PE (n = 77) compared to normal controls (Figure 1b). Both
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of IL-8 (Supplementary
Figure 1).
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Figure S1).
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Figure 1. Liver
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and
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of
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expression
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IL-8
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(a) liver IL-8 mRNA expression (fold-change) and (b) serum IL-8 concentration (pg/mL) in normal controls (NC), disease
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(NC), disease controls
atresia
patients
controls (DC),
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patients
at portoenterostomy
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duringbiliary
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§
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withmRNA
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atpatient
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liver IL-8
expression
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and
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levels
(r
=
0.31,
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At
PE, the
patients
< 0.01, n = 66) and IL-8 serum levels (r = 0.31, p < 0.01, n = 77). At PE, the patients
with
splenic malformation showed lower liver IL-8 mRNA expression (5.51 (3.95–7.22) fold, n =
10) than those without (13.31 (6.37–21.07) fold, n = 54, p = 0.02), but median serum IL-8
concentrations were similar in patients with (164 (116–225) pg/mL, n = 9) and without
(208 (121–381) pg/mL, n = 68, p = 0.44) splenic malformation. IL-8 liver mRNA expression
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with splenic malformation showed lower liver IL-8 mRNA expression (5.51 (3.95–7.22)
fold, n = 10) than those without (13.31 (6.37–21.07) fold, n = 54, p = 0.02), but median
serum IL-8 concentrations were similar in patients with (164 (116–225) pg/mL, n = 9) and
6 of 13
without (208 (121–381) pg/mL, n = 68, p = 0.44) splenic malformation. IL-8 liver mRNA
expression (14.9 ± 10.7 vs. 11.6 ± 9.92) fold, p = 0.288) and serum levels (394 ± 613 vs.
372 ± 204 pg/mL, p = 0.823) were comparable in the London and Helsinki samples.
3.3. Liver IL-8 Expression Predominantly Localized to Cholangiocytes
3.3. Liver
IL-8 Expression
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(Figure
2a). In
BA livers,
enhanced IL-8
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expression was more prominent at PE (Figure 2b) than during the follow up (Figure 2c).
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IL8
and
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IL-8a
HNF6, showing IL-8 expression in bile duct cholangiocytes in the normal liver, and
expression
in
bile
duct
cholangiocytes
in
the
normal
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and
a
predominant
IL-8
exprespredominant IL-8 expression in the DR areas and cholangiocytes instead of hepatocytes
sion
in theatresia
DR areas
and cholangiocytes instead of hepatocytes in biliary atresia patients.
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patients.

Figure 2.
2. Representative
and
in in
situ
hybridization
(ISH)
in (a)
Figure
Representative liver
liverexpression
expressionofofIL-8
IL-8on
onimmunohistochemistry
immunohistochemistry(IHC)
(IHC)
and
situ
hybridization
(ISH)
in
normal
control
(NC),
(b)
biliary
atresia
patient
at
portoenterostomy
(PE)
and
(c)
during
follow-up
(FU)
after
PE.
ISH
(a) normal control (NC), (b) biliary atresia patient at portoenterostomy (PE) and (c) during follow-up (FU) after PE. ISH
includes two magnified images (80×) from each of the original (20×) image focused on (1) the area of ductular reaction
includes two magnified images (80×) from each of the original (20×) image focused on (1) the area of ductular reaction
(DR) and (2) hepatocyte rich parenchymal area. Arrow heads (black and white filled) point to IL-8 expressing cells
(DR) and (2) hepatocyte rich parenchymal area. Arrow heads (black and white filled) point to IL-8 expressing cells (brown
(brown in IHC and green in ISH) while arrows (white filled) point to a hepatocyte marker HNF6 expressing cells in ISH.
in
IHCthe
and
green in of
ISH)
arrows
(white filled) point
a hepatocyte
marker
expressing
cellsininthe
ISH.
Note
expression
IL-8while
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and
and cholangiocytes instead of hepatocytes in biliary atresia patients. Scale bar = 50 μm (20×)/10 μm (80×)
cholangiocytes instead of hepatocytes in biliary atresia patients. Scale bar = 50 µm (20×)/10 µm (80×).

3.4. IL-8 Associated with Liver Fibrosis, Ductular Reaction and Liver Injury
3.4. IL-8 Associated with Liver Fibrosis, Ductular Reaction and Liver Injury
Liver IL-8 mRNA expression correlated positively with the Metavir fibrosis stage at
IL-8
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at
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p =mRNA
0.04, n =expression
51) and incorrelated
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fibrosis markers ACTA2 encoding for α-SMA and COL1A2 encoding for collagen type 1
with fibrosis markers ACTA2 encoding for α-SMA and COL1A2 encoding for collagen type
(Figure 3). Liver IL-8 expression correlated positively with bile ductular proliferation (r =
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4. Discussion
In this study we have comprehensively addressed the prognostic value of liver and
serum expression of IL-8 for PE outcomes in a large number of BA patients in relation to
histological liver fibrosis, (transcriptional) markers of liver fibrogenesis and cholangiocytes
as well as biochemical markers of liver injury. We demonstrated marked parallel increases
in liver and serum expression of IL-8, which were specific for IL-8 among several other
cytokines studied. Although liver IL-8 expression was associated with histological liver
fibrosis, and surrogate markers of liver fibrogenesis as well as bile ductular proliferation
and cholangiocytes at the mRNA level, serum IL-8 levels were associated with further
survival with native liver only in samples obtained during postoperative follow-up after
PE. Our findings suggest that although IL-8 may have a distinctive pathophysiological role
in BA by promoting DR and liver fibrogenesis, prognostic value of serum IL-8 in predicting
PE outcomes is limited to the postoperative follow-up period after PE.
Prolonged immune activation with the release of several proinflammatory cytokines
in the affected liver is considered vital for the developing fibrosis and liver damage in
BA [17]. At the time of PE, an inflammatory infiltrate associated with DR and fibrosis
along the portal tracts occurs [16,18]. Liver fibrosis progresses, also following successful
PE surgery, for largely unknown reasons [15], but has been attributed to activation of
hepatic stellate cells and portal myofibroblasts by cytokines derived from Kupffer cells
and reactive cholangiocytes of DR [3,5,19,20], leading to the deposition of an extra cellular
matrix and collagen. In accordance with previous experimental observations [11], our
findings suggest that IL-8 is involved with the above outlined liver injury cascade in BA,
and that the involvement was specific to IL-8 as several other cytokines studied failed
to show enhanced expression to a comparable degree. Not only was IL-8 distinctively
overexpressed in BA livers, but also correlated with histological fibrosis, bile ductular
proliferation and transcriptional markers of fibrogenesis and cholangiocytes. In addition,
liver IL-8 expression was localized to cholangiocytes in the areas of DR in accordance
with previous findings in adult cholestatic liver diseases [21]. We can only speculate as
to the underlying reasons for the lower correlation of liver IL-8 mRNA expression with
the Metavir stage than with ACTA2 or COL1A2. One possible reason could be that the
Metavir stage is a class variable as opposed to mRNA expression being a continuous
variable, which may skew the correlation between them. There is also a notable overlap
between histological scoring of adjoining Metavir stages, especially between stages 2 and
3. Histological portal inflammation score gives a crude estimation of all inflammatory
cells present in portal areas, and the missing correlation between portal inflammation and
IL-8 expression might be related to similar limitations as outlined above for histological
fibrosis score.
Overexpression of IL-8 peaked at and within one year after PE and gradually decreased
thereafter. The early expression peak may be attributable to the combined effects of
overt cholestasis, vigorous bile ductular proliferation and inflammation before surgical
re-establishment of bile flow as well as plausibly causative viral infection directly inflicting
the initial bile duct damage [1,3,17]. The fact that liver IL-8 expression showed only limited
prognostic value for PE outcomes suggest a non-decisive but complementary role of IL-8
as an indicator for the success of PE or as a mediator for the progression of postoperative
liver injury in BA. Contrary to liver IL-8 expression, serum IL-8 showed no association with
histological liver fibrosis and only weak correlations with surrogate markers of liver injury
measured by qPCR, explaining the poor predictive value of serum IL-8 at PE. Our findings
are in accordance with a recent study among 57 BA patients, where serum and liver IL-8
concentration measured at PE was unrelated to 2-year native liver survival following
PE [14].
Interestingly, the increased post-PE expression profile of serum IL-8 followed that of
cholangitis episodes, frequency of which is reported to predominate the first postoperative
year with a prompt subsequent decline [22–24]. It has been previously shown that expression of IL-8 in human biliary epithelial cells is stimulated by proinflammatory cytokines
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IL-1β and TNF-α, and lipopolysaccharide produced by gram negative bacteria, which
are commonly causative microbes underlying BA associated cholangitis [21,23,25,26]. In
the early disease phase, enhanced secretion by an augmented peripheral immature B-cell
population seems to be an important source of elevated serum IL-8 [27]. Serum TNF-α
and IL-18 levels have been shown to be significantly increased within 6 months of PE
surgery [28]. Here, liver and serum expression patterns of TNF-α followed those of IL-8
and their liver mRNA expression correlated with each other. Based on these data, we
hypothesize that besides persisting DR, bacterial cholangitis may have contributed to the
increased postoperative serum IL-8 levels, and may help to explain their association with
native liver survival as recurrent postoperative cholangitis episodes are known to relate
with the need of liver transplantation following PE [29].
In accordance with previous reports, serum IL-8 levels positively correlated with
biochemical liver injury markers such as bilirubin, GGT and transaminases during postoperative follow-up, reflecting progression of cholestasis and liver injury [30]. The significant
correlation of IL-8 with bile ductular proliferation and GGT both at PE and during followup reinforces the connection between IL-8 and bile duct injury at both time points. We
hypothesize that the increased serum IL-8 levels mainly reflected active DR, while postoperative serum levels may have been contributed by bacterial cholangitis. However, the
shift from a predominantly inflammatory liver injury phenotype at PE to the one predominated by DR and fibrosis may have also allowed their more specific detection and accurate
prediction by serum IL-8 during follow-up [15,31].
The main limitations of this study include the retrospective design, which is unavoidably associated with inaccuracies in data collection and missing data points. Although
we were not able to prospectively include consecutive patients, PE age, occurrence of
associated malformations, anatomic type of BA, clearance of jaundice rate and native liver
survival among the included patients were well represented in previously described BA
cohorts from Europe [32,33]. While we were able to include a relatively large number
of BA patients at PE and during follow-up, the number of patients with simultaneous
postoperative liver and serum specimens remained limited. Moreover, serum samples
were not collected during cholangitis episodes, precluding our ability to address the actual
relationship between serum IL-8 concentration and cholangitis, which should be addressed
in future studies. Most of the follow-up serum IL-8 measurements were performed after
2 years of PE, which introduces a selection bias and precludes any conclusions regarding
the early postoperative period. Finally, our findings concerning follow-up studies may not
be generalizable to patient cohorts with different postoperative treatment regimens.
5. Conclusions
Our data showed significant and distinctive overexpression of IL-8 by cholangiocytes
within DR in BA patients both at PE and during postoperative follow-up. Despite the IL-8
overexpression in the liver, increased serum IL-8 levels associated weakly with decreased
native liver survival only during the postoperative period following PE.
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